Department of Pharmaceutics, School of Pharmacy, Fudan University and Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, People's Republic of China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, People's Republic of China.
J Nanobiotechnology. 2023 Aug 4;21(1):253. doi: 10.1186/s12951-023-02006-x.
Inhibition of tumor growth and normalization of immune responses in the tumor microenvironment (TME) are critical issues for improving cancer therapy. However, in the treatment of glioma, effective nanomedicine has limited access to the brain because of the blood-brain barrier (BBB). Previously, we demonstrated nano-sized ginseng-derived exosome-like nanoparticles (GENs) consisting of phospholipids including various bioactive components, and evaluated anti-tumor immune responses in T cells and Tregs to inhibit tumor progression. It was found that the enhanced targeting ability of GENs to the BBB and glioma induced a significant therapeutic effect and exhibited strong efficacy in recruiting M1 macrophage expression in the TME. GENs were demonstrated to be successful candidates in glioma therapeutics both in vitro and in vivo, suggesting excellent potential for inhibiting glioma progression and regulating tumor-associated macrophages (TAMs).
抑制肿瘤生长和肿瘤微环境（TME）中的免疫反应正常化是改善癌症治疗的关键问题。然而，在治疗脑胶质瘤时，由于血脑屏障（BBB）的存在，有效的纳米医学药物很难进入大脑。此前，我们证明了由磷脂组成的纳米人参衍生的类外泌体纳米颗粒（GENs）包含各种生物活性成分，并评估了 T 细胞和 Tregs 中的抗肿瘤免疫反应，以抑制肿瘤进展。结果发现，GENs增强了对 BBB 和脑胶质瘤的靶向能力，从而显著提高了治疗效果，并在 TME 中强烈表达募集 M1 巨噬细胞。GENs 在体外和体内均被证明是脑胶质瘤治疗的成功候选药物，这表明其具有抑制脑胶质瘤进展和调节肿瘤相关巨噬细胞（TAMs）的巨大潜力。
